Cochrane · systematic review · CD012380
Interventions for chronic kidney disease in people with sickle cell disease
Roy, NBA, Carpenter, A, Dale-Harris, I, et al. · Cochrane Database of Systematic Reviews · 2023 · Cochrane Library
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
12
current version
GRADE rated
5
No studies
7
Included studies
NR
No studies 7 · 58.3%Ungraded 0 · 0%Very low 3 · 25%Low 2 · 16.7%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Current version onlyHydroxyurea compared to placebo for preventing or reducing kidney complications in people with sickle cell disease
Population: people with sickle cell disease
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Reduction or prevention of kidney disease progression Hydroxyurea vs placebo | no estimate extracted | 1 study · 142 participants | Very low Downgraded: risk of bias, indirectness |
Serious adverse events Hydroxyurea vs placebo | RR 0.39 [0.13, 1.16] | 1 study · 193 participants | Low Downgraded: imprecision, indirectness |
All‐cause mortality Hydroxyurea vs placebo | no estimate extracted | 1 study · 193 participants | Low Downgraded: imprecision, indirectness |
Quality of life Hydroxyurea vs placebo | no estimate extracted | NR | No studies |
Angiotensin‐converting enzyme inhibitors compared to placebo for preventing or reducing kidney complications in people with sickle cell disease
Population: people with sickle cell disease
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Reduction or prevention of kidney disease progression Angiotensin‐converting enzyme inhibitors vs placebo | no estimate extracted | 1 study · 22 participants | Very low Downgraded: risk of bias, imprecision, indirectness |
Serious adverse events Angiotensin‐converting enzyme inhibitors vs placebo | no estimate extracted | NR | No studies |
All‐cause mortality Angiotensin‐converting enzyme inhibitors vs placebo | no estimate extracted | NR | No studies |
Quality of life Angiotensin‐converting enzyme inhibitors vs placebo | no estimate extracted | NR | No studies |
Angiotensin‐converting enzyme inhibitors compared to vitamin C for preventing or reducing kidney complications in people with sickle cell disease
Population: children with sickle cell anaemia and microalbuminuria
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Reduction or prevention of kidney disease progression Angiotensin‐converting enzyme inhibitors vs vitamin C | no estimate extracted | 1 study · 170 participants | Very low Downgraded: risk of bias, imprecision |
Serious adverse events Angiotensin‐converting enzyme inhibitors vs vitamin C | no estimate extracted | NR | No studies |
Mortality due to any cause Angiotensin‐converting enzyme inhibitors vs vitamin C | no estimate extracted | NR | No studies |
Quality of life Angiotensin‐converting enzyme inhibitors vs vitamin C | no estimate extracted | NR | No studies |
Hydroxyurea compared to placebo for preventing or reducing kidney complications in people with sickle cell disease
Population: people with sickle cell disease
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Slower progression or improvement in GFR mL per min per 1.73 m² (measured at 18 to 24 months) Hydroxyurea vs placebo | no estimate extracted | 1 study · 142 participants | Very low Downgraded: risk of bias, indirectness |
Improvement in ability to concentrate urine mOsm/kg (measured at 18 to 24 months) Hydroxyurea vs placebo | no estimate extracted | 1 study · 178 participants | Low Downgraded: imprecision, indirectness |
SAEs Hydroxyurea vs placebo | RR 0.39 [0.13, 1.16] | 1 study · 193 participants | Low Downgraded: imprecision, indirectness |
SAEs Hydroxyurea vs placebo | RR 0.68 [0.45, 1.02] | 1 study · 193 participants | Low Downgraded: imprecision, indirectness |
SAEs Hydroxyurea vs placebo | RR 0.83 [0.68, 1.01] | 1 study · 193 participants | Low Downgraded: imprecision, indirectness |
Mortality due to any cause Hydroxyurea vs placebo | no estimate extracted | 1 study · 193 participants | Low Downgraded: imprecision, indirectness |
Quality of life Hydroxyurea vs placebo | no estimate extracted | NR | No studies |
ACEI compared to placebo in preventing or reducing kidney complications in people with sickle cell disease
Population: people with sickle cell disease
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Slower progression or reduction in proteinuria (mg/day 6 months ACEI vs placebo | no estimate extracted | 1 study · 22 participants | Very low Downgraded: risk of bias, imprecision, indirectness |
Improvement in ability to concentrate urine mOsm/kg ACEI vs placebo | no estimate extracted | NR | No studies |
SAEs ACEI vs placebo | no estimate extracted | NR | No studies |
SAEs ACEI vs placebo | no estimate extracted | NR | No studies |
SAEs ACEI vs placebo | no estimate extracted | NR | No studies |
Mortality due to any cause ACEI vs placebo | no estimate extracted | NR | No studies |
Quality of life ACEI vs placebo | no estimate extracted | NR | No studies |